MB Research is a prominent proponent of modern cell- and mechanistic-based solutions and has a market-leading position in in vitro toxicological testing in the US for the cosmetic, consumer product and industrial chemical industries.
“I am very happy to sign an agreement with another CRO and with such a strong player as MB Research Labs. By adding an additional CRO to our sales channels in the US, we have now given more end customers access to our innovative tests. In addition, with a driven and respected partner, we are increasing the possibilities of accelerating a change throughout the toxicological testing industry,” says Anki Malmborg Hager, CEO of SenzaGen.
The collaboration with MB Research Labs is in line with SenzaGen’s strategy to recruit strong CRO and industrial partners in several market segments and geographies. The United States is an important market that currently accounts for just over one third of the global market for cell based in vitro testing. There is also a keen interest in animal-free and alternative test methods with introductions in legislation of bans on animal testing for cosmetic and other products. California is the first state to pass this type of legislation and the US market is expected to grow as more states face similar bans.
“As a leading provider of in vitro toxicity testing to the US and worldwide, we always want to use the latest predictive and innovative methods, to provide the best in vitro toxicology solutions to our customers. GARD™ delivers all this, and we look forward to a fruitful collaboration”, states George DeGeorge, Ph.D. DABT, Chief Scientific Officer at MB Research Labs.
SenzaGen’s GARD™ product portfolio consists of a set of allergy tests with industry leading performance and accuracy. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence, and replace animal experiments for the cosmetics, chemical and pharmaceutical industries for their tests on whether chemical substances in products can be allergenic.
The SenzaGen’s GARD™ portfolio will be presented on 10-14 March 2019 at the SOT Society of Tocicology’s 58th Annual Meeting and ToxExpo (Booth #3652) in Baltimore, USA.
This information is information that SenzaGen is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above on March 7, 2019, at 08.30 CET.
GARD™ consists of a group of tests for analyzing chemicals’ ability to start an allergic reaction in humans. By analyzing hundreds of markers, GARD™ generates large amounts of data and delivers results with over 90 percent accuracy. This can be compared to today’s standard method – tests on mice – which only achieves 70-75 percent precision. SenzaGen’s test can also quantify the allergenic potential of a chemical substance.
About MB Research Labs
Since 1972, MB Research Labs has offered toxicology testing services to the cosmetic, consumer product, agri-chemical, biotechnology and pharmaceutical industries. A leading CRO with over 30 years’ experience in the in vitro/alternative and mechanistic toxicity testing field, we maintain a prominent position in non-animal testing in the US, EU and many other countries, MBRL is always ready to adopt, as well as invent new non-animal-based predictive toxicity testing technologies. Our laboratories offer GLP assays in full compliance with OECD, FDA and EPA test guidelines, as well as custom-designed toxicity evaluations.
About SenzaGen AB
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. The tests are sold via license laboratories (CRO) and distributors, and via the headquarters in Lund and the sales office in the US. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the USA. For more information visit http://www.senzagen.com.
SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399 firstname.lastname@example.org, is the company’s Certified Adviser. For more information, please visit http://www.senzagen.com.